Pictet Asset Management SA Makes New $56,000 Investment in 23andMe Holding Co. (NASDAQ:ME)

Pictet Asset Management SA bought a new stake in 23andMe Holding Co. (NASDAQ:MEGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,729 shares of the company’s stock, valued at approximately $56,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of 23andMe by 259.1% in the 1st quarter. Vanguard Group Inc. now owns 17,551,125 shares of the company’s stock valued at $67,221,000 after purchasing an additional 12,663,268 shares in the last quarter. BlackRock Inc. boosted its stake in shares of 23andMe by 121.7% in the 1st quarter. BlackRock Inc. now owns 3,128,372 shares of the company’s stock valued at $11,980,000 after purchasing an additional 1,717,071 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of 23andMe in the 1st quarter valued at $7,692,000. Prescott General Partners LLC boosted its stake in shares of 23andMe by 26.0% in the 1st quarter. Prescott General Partners LLC now owns 1,423,829 shares of the company’s stock valued at $5,453,000 after purchasing an additional 293,450 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of 23andMe by 280.0% in the 1st quarter. State Street Corp now owns 1,185,035 shares of the company’s stock valued at $4,539,000 after purchasing an additional 873,217 shares in the last quarter. Institutional investors and hedge funds own 21.64% of the company’s stock.

Analysts Set New Price Targets

ME has been the subject of a number of research analyst reports. Cowen initiated coverage on 23andMe in a report on Thursday, September 22nd. They issued an “outperform” rating and a $6.00 price target for the company. Credit Suisse Group cut their price target on 23andMe from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Tuesday, November 8th. Finally, Cowen initiated coverage on 23andMe in a report on Thursday, September 22nd. They issued an “outperform” rating and a $6.00 price target for the company.

23andMe Trading Up 3.5 %

Shares of NASDAQ:ME opened at 2.92 on Friday. The stock has a market capitalization of $1.33 billion, a P/E ratio of -4.06 and a beta of 1.24. 23andMe Holding Co. has a 1-year low of 2.12 and a 1-year high of 9.64. The business has a 50-day moving average price of 3.02 and a two-hundred day moving average price of 3.03.

23andMe Company Profile

(Get Rating)

23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.

See Also

Want to see what other hedge funds are holding ME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 23andMe Holding Co. (NASDAQ:MEGet Rating).

Institutional Ownership by Quarter for 23andMe (NASDAQ:ME)

Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.